Showing 1171-1180 of 5128 results for "".
- Castle Bioscience’s DecisionDx-SCC Test Boosts Mohs Surgeons' Confidencehttps://practicaldermatology.com/news/castle-biosciences-decisiondx-scc-test-boosts-mohs-surgeons-confidence/2461382/Castle Bioscience’s DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions, according to data presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. DecisionD
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i
- ASDSA Names 2022 Patient Safety Hero Awardeeshttps://practicaldermatology.com/news/asdsa-names-2022-patient-safety-hero-awardees/2461379/Mathew Avram, MD, JD and Joel Cohen, MD received the
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- Spotlight On: Honey and Its Role in Wound Healinghttps://practicaldermatology.com/news/spotlight-on-honey/2461353/Honey may play a role in wound healing due to its antimicrobial and tissue-regenerative properties, according to scientists from the University of Manchester. Their review of more than 250 articles spans 85 years -with oldest article from 1937- is published in the journal Pharmaceu
- EADV News: ‘Healthy’ Suntan Myths Persist in Europehttps://practicaldermatology.com/news/eadv-news-healthy-suntan-myths-persist-in-europe/2461338/Fully eight in 10 Europeans believe tans are attractive with almost as many (73%) saying tans are healthy, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. Results from a survey, conducted by La Roche-Posay Laboratoires and
- UK Study: Psoriasis Diagnoses in Primary Care Delayed by Up to 5 Yearshttps://practicaldermatology.com/news/uk-study-psoriasis-diagnoses-in-primary-care-delayed-by-up-to-5-years/2461322/Psoriasis may be underdiagnosed in UK primary care settings, according to research out of the University of Manchester in The British Journal of General Practice. Patients who are later diagnosed with psoriasis are twice as likely to be prescribed steroid or antifungal creams t
- New Partnership for Revision Skincare, RVL Pharmaceuticalshttps://practicaldermatology.com/news/new-partnership-for-revision-skincare-rvl-pharmaceuticals/2461320/With a goal to collaborate on a variety of marketing efforts within the medical aesthetics industry, Revision Skincare® and RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, are partnering to address what they see as significant unmet consumer needs. Revisions